• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

避免事后诸葛亮:医药专利非显而易见性判断的判例法回顾与 KSR v Teleflex 判决的指导意义。

Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision.

机构信息

CSIR Unit for Research and Development of Information Products "Tapovan" S.No. 113 & 114, Pune, Maharasthra, India.

Academy of Scientific and Innovative Research (AcSIR), CSIR-HRDC, Ghaziabad, Uttar Pradesh, India.

出版信息

Expert Opin Ther Pat. 2021 Oct;31(10):951-963. doi: 10.1080/13543776.2021.1931121. Epub 2021 May 26.

DOI:10.1080/13543776.2021.1931121
PMID:33993810
Abstract

: Hindsight bias is the tendency to estimate an outcome once it is known. Legal systems are often prone to hindsight bias. In patent law, the non-obviousness or inventive step is the most critical determinant of patentability and often subjected to hindsight bias.: Scholarly literature confirms the existence of hindsight bias in different patent systems. This communication hence addresses factors, which lead to hindsight bias specifically in chemical and pharmaceutical arts, guidance from the case law that can be helpful in avoiding hindsight bias in non-obviousness determination.: The Supreme Court in 2007, advocated a more expansive and flexible approach to where the Teaching Suggestion or Motivation test could come from. In the case of chemical and pharmaceutical active compounds, the considerations such as i) was there sufficient motivation to modify the lead compound and arrive at the claimed compound and its properties, ii) was there a reasonable expectation of success to achieve the claimed property and other such considerations highlighted in this review may contribute to avoid hindsight bias in non-obviousness determination.

摘要

后视偏差是指在结果已知的情况下进行估计的倾向。法律制度往往容易受到后视偏差的影响。在专利法中,非显而易见性或创造性步骤是可专利性的最关键决定因素,往往容易受到后视偏差的影响。学术文献证实了不同专利系统中存在后视偏差。因此,本通信专门针对化学和制药领域导致后视偏差的因素进行了讨论,并提供了判例法中的指导意见,以帮助避免非显而易见性判断中的后视偏差。2007 年,最高法院主张采取更广泛和灵活的方法来确定教学启示或动机测试可以来自何处。在化学和制药活性化合物的情况下,需要考虑以下因素:i)是否有足够的动机来修改先导化合物并获得所要求的化合物及其性质;ii)是否有合理的成功预期来实现所要求的性质以及本综述中强调的其他类似因素,这些因素可能有助于避免非显而易见性判断中的后视偏差。

相似文献

1
Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision.避免事后诸葛亮:医药专利非显而易见性判断的判例法回顾与 KSR v Teleflex 判决的指导意义。
Expert Opin Ther Pat. 2021 Oct;31(10):951-963. doi: 10.1080/13543776.2021.1931121. Epub 2021 May 26.
2
Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.显而易见性、后见之明与视角:凯斯诉泰利福案对生物技术和制药专利的影响
Nat Biotechnol. 2007 Oct;25(10):1105-6. doi: 10.1038/nbt1007-1105.
3
Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.针对联邦法院裁决,加强药品发明专利保护的策略。
Curr Top Med Chem. 2010;10(18):1929-36. doi: 10.2174/156802610793176701.
4
Nonobviousness of pharmaceutical inventions: implications for patent prosecution and litigation.制药发明的非显而易见性:对专利申请和诉讼的影响
Pharm Pat Anal. 2019 Jul;8(4):91-107. doi: 10.4155/ppa-2019-0014. Epub 2019 Aug 15.
5
KSR v. Teleflex. Part 1: Impact of U.S Supreme Court Patent Law on Canadian intellectual property and regulatory rights landscape.
Health Law J. 2007;15:221-46.
6
Pharmaceutical patent life-cycle management after KSR v. Teleflex.KSR诉泰利福公司案后的药品专利生命周期管理
Food Drug Law J. 2008;63(1):275-320.
7
Pharmaceutical patent law: the Canadian perspective.制药专利法:加拿大视角
Pharm Pat Anal. 2016 Jul;5(4):271-9. doi: 10.4155/ppa-2016-0007. Epub 2016 Jun 27.
8
KSR Int'l Co. v. Teleflex, Inc.: no obvious changes for the biotechnology market.KSR国际公司诉泰利福公司案:对生物技术市场无明显影响。
Yale J Biol Med. 2007 Dec;80(4):153-7.
9
What is your reasonable expectation of success in obtaining pharmaceutical or biotechnology patents having nonobvious claimed inventions that the courts will uphold? An overview of obviousness court decisions.对于获得法院会支持的具有非显而易见的权利要求发明的制药或生物技术专利,你对成功的合理期望是什么?显而易见性法院判决概述。
Cold Spring Harb Perspect Med. 2014 Dec 4;5(4):a020875. doi: 10.1101/cshperspect.a020875.
10
Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.鉴定导致生物技术专利显而易见性裁决的因素:对 KSR 之后美国联邦巡回上诉法院判决的最新分析。
Hum Vaccin Immunother. 2013 Nov;9(11):2490-5. doi: 10.4161/hv.25822. Epub 2013 Jul 30.